Literature DB >> 22406956

Clinical and biologic features of patients suspected or confirmed to have heparin-induced thrombocytopenia in a cardiothoracic surgical ICU.

Virginie Trehel-Tursis1, Virginie Louvain-Quintard2, Youssef Zarrouki1, Audrey Imbert1, Sylvie Doubine2, François Stéphan3.   

Abstract

BACKGROUND: The diagnosis of heparin-induced thrombocytopenia (HIT) is problematic in the surgical ICU, as there are multiple potential explanations for thrombocytopenia. We conducted a study to assess the incidence, clinical presentation, and outcome of HIT in a cardiothoracic surgical ICU.
METHODS: From January 2005 to December 2010, all patients with suspicion of HIT were prospectively identified, and data were collected retrospectively. Detection of anti-PF4/heparin antibodies and functional assays were systematically performed.
RESULTS: During the study period, 5,949 patients were admitted to the ICU (2,751 after cardiac surgery and 3,198 after thoracic surgery), of whom 101 were suspected to have HIT(1.7% [95% CI, 1.4%-2.0%]). Suspicion of HIT occurred at a median of 5 (4-9) days after ICU admission. Diagnosis was confirmed in 28 of 5,949 patients (0.47% [95% CI, 0.33%-0.68%]).Thrombosis was detected in 14 patients with HIT (50%) and in 12 patients without HIT (16%)( P 5 .0006). After receiver operating characteristic analysis (area under curve 5 0.78 0.06),a 4Ts score ≥ 5 had a sensitivity of 86% and a specificity of 70%. Course of platelet count was similar between the two groups. Six patients (21%) with HIT and 20 (27%) without died( P 5 .77).
CONCLUSIONS: Even with a prospective platelet monitoring protocol, suspicion for HIT arose in <2% of patients in a cardiothoracic ICU. Most were found to have other causes of thrombocytopenia,with HIT confirmed in 28 of 101 suspected cases (0.47% of all patients in the ICU). The 4Ts score may have value by identifying patients who should have laboratory testing performed.The mortality of patients with HIT was not different from other very ill thrombocytopenic patients in the ICU.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22406956     DOI: 10.1378/chest.11-3074

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  11 in total

1.  Thrombocytopenia: A Risk Factor of Mortality for Patients with Sepsis in the Intensive Care Unit.

Authors:  Bünyamin Burunsuzoğlu; Cüneyt Saltürk; Zuhal Karakurt; Esra Akkütük Öngel; Huriye Berk Takır; Feyza Kargın; Gülbanu Horzum; Merih Balcı; Özlem Moçin; Nalan Adıgüzel; Gökay Güngör; Adnan Yılmaz
Journal:  Turk Thorac J       Date:  2015-12-14

2.  PF4-heparin antibodies during ECMO: incidence, course, and outcomes.

Authors:  Florent Laverdure; Virginie Louvain-Quintard; Talna Kortchinsky; Saïda Rezaiguïa-Delclaux; Audrey Imbert; François Stéphan
Journal:  Intensive Care Med       Date:  2016-02-22       Impact factor: 17.440

Review 3.  Diagnosis and management of heparin-induced thrombocytopenia.

Authors:  Grace M Lee; Gowthami M Arepally
Journal:  Hematol Oncol Clin North Am       Date:  2013-04-13       Impact factor: 3.722

4.  Prevalence and clinical implications of anti-PF4/heparin antibodies in intensive care patients: a prospective observational study.

Authors:  Sixten Selleng; Kathleen Selleng; Sigrun Friesecke; Matthias Gründling; Sven-Olaf Kuhn; Ricarda Raschke; Olivia J Heidecke; Carsten Hinz; Gregor Hron; Theodore E Warkentin; Andreas Greinacher
Journal:  J Thromb Thrombolysis       Date:  2015-01       Impact factor: 2.300

Review 5.  Molecular and cellular pathogenesis of heparin-induced thrombocytopenia (HIT).

Authors:  Lubica Rauova; Gowthami Arepally; Mortimer Poncz; Douglas B Cines
Journal:  Autoimmun Rev       Date:  2018-08-10       Impact factor: 9.754

Review 6.  Heparin-induced thrombocytopenia during extracorporeal life support: incidence, management and outcomes.

Authors:  Jae Hwan Choi; Jessica G Y Luc; Matthew P Weber; Haritha G Reddy; Elizabeth J Maynes; Avijit K Deb; Louis E Samuels; Rohinton J Morris; H Todd Massey; Antonio Loforte; Vakhtang Tchantchaleishvili
Journal:  Ann Cardiothorac Surg       Date:  2019-01

7.  Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial.

Authors:  Louise Schilder; S Azam Nurmohamed; Frank H Bosch; Ilse M Purmer; Sylvia S den Boer; Cynthia G Kleppe; Marc G Vervloet; Albertus Beishuizen; Armand R J Girbes; Pieter M Ter Wee; A B Johan Groeneveld
Journal:  Crit Care       Date:  2014-08-16       Impact factor: 9.097

8.  Argatroban versus Lepirudin in critically ill patients (ALicia): a randomized controlled trial.

Authors:  Tanja A Treschan; Maximilian S Schaefer; Johann Geib; Astrid Bahlmann; Tobias Brezina; Patrick Werner; Elisabeth Golla; Andreas Greinacher; Benedikt Pannen; Detlef Kindgen-Milles; Peter Kienbaum; Martin Beiderlinden
Journal:  Crit Care       Date:  2014-10-25       Impact factor: 9.097

Review 9.  Heparin Induced Thrombocytopenia for the Perioperative and Critical Care Clinician.

Authors:  Ingrid Moreno-Duarte; Kamrouz Ghadimi
Journal:  Curr Anesthesiol Rep       Date:  2020-08-29

10.  Relationship between the 4Ts scoring system and the antiplatelet factor 4/heparin antibodies test in critically ill patients.

Authors:  Yosuke Matsumura; Taka-Aki Nakada; Shigeto Oda
Journal:  Acute Med Surg       Date:  2013-12-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.